Acknowledgements

We are grateful to Genethon for providing us with retroviral supernatants through the Therapeuskin consortium, to Dagmar Wirth for the Flp293A-E1aColVII1 producer clone and to Alain Hovnanian for stimulating discussions. We are also grateful to Steeve Vermot and Jeanne Vannod for excellent technical help, to Patrick Reichenbach and Giulietta Maruggi for the help in Southern blotting, to Matthias Titeux for sharing his grafting protocol and to Stéphanie Rosset for technical assistance with TEM. We also thank Olivier Dormond for pRb, p21, Ras and GAPDH antibodies, Alessandro Amici for help with the tumorigenic assay and critical reading of the manuscript, Jean-Daniel Tissot for supplying us with human plasma, Alvaro Baptista and the Department of Pathology at the CHUV with skin samples and Rainer Follador from Microsynth for helpful discussion. We are particularly grateful to continuing support from La Fondation Enfants Papillons and Dr Elisabeth Gianadda, DEBRA-CH and the patient's family. YB was supported by the EPFL, the CHUV and the European Commission through the 6th (Therapeuskin) and 7th (Opti-Stem) framework programmes. FM was supported by the Italian Ministry of Health, the Progetto Malattie Rare (RF-EMR-2008-1210900) and the European Research Council (ERC-2010-AdG, GT-Skin).

Author contributions

SD-GL performed the experiments, organised the collaborative work and inter-

Bianco P, Barker R, Brus Goldstein L, Lindvall therapies under atta 1489–1495

Bianco P, Cao X, Frenett (2013b) The meaning science of mesenchy

Biffi A, Montini E, Loriol S, Calabria A, Canale therapy benefits me

Bonfanti P, Claudinot S, (2010) Microenviron skin multipotent ste

Bruckner-Tuderman L, H anchoring fibrils: less

Biol 18: 43-54

Buchholz CJ, Sanzenbac exemption clause-ne

Cartier N, Hacein-Bey-A Kutschera I, Vidaud I Hematopoietic stem


adrenoleukodystroph

Published online: February 27, 2015

Research Article







A single epidermal stem cell strategy for safe ex vivo gene therapy

Stéphanie Droz-Georget Lathion^{1,2}, Ariane Rochat^{1,2}, Graham Knott³, Alessandra Recchia⁴, Danielle Martinet⁵, Sara Benmohammed⁶, Nicolas Grasset^{1,2}, Andrea Zaffalon^{1,2}, Nathalie Besuchet Schmutz⁵, Emmanuelle Savioz-Dayer^{1,2}, Jacques Samuel Beckmann^{5,6}, Jacques Rougemont⁷, Fulvio Mavilio^{4,8} & Yann Barrandon^{1,2,*}

Abstract

There is a widespread agreement from patient and professional organisations alike that the safety of stem cell therapeutics is of paramount importance, particularly for ex vivo autologous gene therapy. Yet current technology makes it difficult to thoroughly evaluate the behaviour of genetically corrected stem cells before they are transplanted. To address this, we have developed a strat-

Keywords cell therapy; regulatory affairs; stem cells; wound healing
Subject Categories Regenerative Medicine; Stem Cells; Skin
DOI 10.15252/emmm.201404353 | Received 18 June 2014 | Revised 8 January
2015 | Accepted 21 January 2015

Introduction